Covid and Johnson & Johnson JNJ Revenue Q3 2021

Johnson & Johnson said in its earnings report on Tuesday that it sold $ 502 million of its Covid-19 vaccine in the third quarter, beating Wall Street’s earnings expectations.

According to Refinitiv’s average estimates, J&J has fared compared to Wall Street expectations as follows:

  • Adjusted earnings per share: $ 2.60 per share versus expected $ 2.35.
  • Revenue: $ 23.34 billion versus $ 23.72 billion expected.

J & J’s shares rose more than 1% in pre-trading hours.

J & J’s report was overshadowed by criticism about how it dealt with the opioid crisis and the development of a comparatively less effective Covid vaccine under outgoing CEO Alex Gorsky.

In a press release, Gorsky said the financial results “show solid performance from Johnson & Johnson, driven by robust outperformance in pharmaceuticals, continued recovery in medical devices and strong growth in consumer health.”

This is a developing story. Please check again for updates.

Correction: This story has been updated to reflect that J&J missed its sales estimates.

Leave your vote

0 points
Upvote Downvote

Related Articles

Log In

Forgot password?

Don't have an account? Register

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.